Despite advances in conventional treatments for cystic fibrosis (CF),
the disease is still associated with significant morbidity and mortali
ty, The cloning of the cystic fibrosis transmembrane conductance regul
ator (CFTR) gene and the understanding of the functions of the CFTR pr
otein have led to the development of novel treatment strategies, inclu
ding gene therapy. Here, we review the underlying molecular defect in
CF cells, and the progress in gene-transfer studies from in vitro work
through to clinical trials. We discuss the problems encountered, the
end points used to assess efficacy, and the likely future directions o
f the field.